Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Total Current Liabilities (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Total Current Liabilities for 4 consecutive years, with $10.1 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 33.84% to $10.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.1 million through Dec 2025, down 33.84% year-over-year, with the annual reading at $10.1 million for FY2025, 33.84% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $10.1 million at Spruce Biosciences, up from $9.4 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $24.5 million in Q4 2023, with the low at $8.1 million in Q2 2025.
  • Average Total Current Liabilities over 4 years is $15.1 million, with a median of $13.4 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities surged 156.38% in 2023, then tumbled 50.98% in 2024.
  • Over 4 years, Total Current Liabilities stood at $12.4 million in 2022, then surged by 96.55% to $24.5 million in 2023, then tumbled by 37.68% to $15.2 million in 2024, then plummeted by 33.84% to $10.1 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $10.1 million, $9.4 million, and $8.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.